How often should Prostate Specific Antigen (PSA) levels be checked?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PSA Screening Frequency

For men who choose to undergo PSA screening after shared decision-making, check PSA every 1-2 years for those with PSA ≥1.0 ng/mL, and every 2-4 years for those with PSA <1.0 ng/mL. 1

Screening Intervals Based on PSA Level

Men with PSA <1.0 ng/mL:

  • Screen every 2-4 years, as these men have minimal risk of developing advanced prostate cancer (only 0.23% at 4 years and 0.49% at 8 years). 1
  • Extended intervals reduce unnecessary testing while maintaining mortality benefits. 1
  • Men aged 45-49 with PSA ≤1.0 ng/mL can defer additional testing until age 50. 2

Men with PSA ≥1.0 ng/mL but <2.5 ng/mL:

  • Screen every 1-2 years, as these men have higher risk of developing prostate cancer. 2, 1
  • The NCCN uniformly recommends this interval for men with PSA >1.0 ng/mL. 2

Men with PSA ≥2.5 ng/mL:

  • Screen annually according to the American Cancer Society. 2
  • These men warrant more frequent monitoring due to elevated baseline risk. 2

Evidence Supporting Biennial vs. Annual Screening

The European ERSPC trial data demonstrates that biennial screening (every 2 years) provides comparable survival benefits to annual screening while significantly reducing harms: 2

  • Biennial screening reduces overdiagnosis by approximately 13% compared to annual screening (2.4% vs 3.3%). 2
  • It decreases total tests by 59% and false-positive results by 50%. 2
  • The average delay in diagnosis when moving from annual to biennial screening is only 5-6 months. 1

However, screening every 2 years (compared to every 4 years) showed a 43% reduction in advanced prostate cancer diagnosis but also a 46% increase in low-risk prostate cancer diagnosis. 2

Age-Specific Considerations

Starting Age:

  • Begin at age 45 for most men according to NCCN guidelines. 1
  • Begin at age 40-45 for high-risk men (African American men, those with first-degree relatives diagnosed before age 65, or multiple family members with prostate cancer). 2, 1
  • Average-risk men can begin at age 50 according to the American Cancer Society. 2

Stopping Age:

  • Consider discontinuing routine screening at age 70 for most men. 1
  • Very few men older than 75 benefit from PSA testing. 1
  • Only screen men with at least 10-year life expectancy regardless of age. 2, 1
  • For men over 70, individualize decisions based on health status and consider raising the PSA threshold for biopsy to reduce overdiagnosis. 1

Critical Caveats

Always engage in shared decision-making before initiating PSA screening, discussing potential benefits (small reduction in prostate cancer mortality) and harms (false-positives, overdiagnosis, treatment complications including erectile dysfunction and incontinence). 2, 1, 3

The US Preventive Services Task Force found that PSA screening in men aged 55-69 may prevent approximately 1.3 prostate cancer deaths per 1,000 men screened over 13 years, but causes significant harms including that 1 in 5 men undergoing radical prostatectomy develop long-term urinary incontinence and 2 in 3 experience long-term erectile dysfunction. 3

Baseline PSA in men in their 40s is a stronger predictor of future prostate cancer risk than family history or race alone, supporting the rationale for early baseline testing to guide future screening intervals. 1

References

Guideline

PSA Screening Frequency Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.